Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods

ABSTRACT

Introduction

Psoriasis is a chronic systemic inflammatory disease manifesting as erythematous and desquamative dermatoses.

Objectives

This study estimated the cost per responder (CPR) for the treatment of moderate-to-severe plaque psoriasis with biologic therapies approved by the Colombian regulatory agency.

Methods

This secondary study used a modeling based CPR estimation to evaluate psoriasis therapies in Colombia. We calculated CPR of achieving Psoriasis Area and Severity Index (PASI) scores of 75, 90, and 100 for biological treatments based on the number needed to treat (NNT), reported in previously published network meta-analyses. We calculated CPR for the first year and for the maintenance period. We ranked alternatives using the estimated CPR from each literature source using the Borda count method.

Results

Adalimumab, infliximab and etanercept were the least expensive alternatives. Ixekizumab, guselkumab and secukinumab were the treatments with the lowest NNT for PASI 75, 90, and 100. For both first year and maintenance periods, adalimumab, infliximab, guselkumab and ixekizumab had the lowest CPR. Sensitivity analyzes showed consistent results.

Conclusions

The application of CPR analysis of biologics to treat plaque psoriasis demonstrated that adalimumab, infliximab, guselkumab, and ixekizumab had the lowest CPR in the first year of treatment and during the maintenance period.

KEYWORDS:

• Biological therapies
• Colombia
• cost per responder
• moderate-to-severe plaque psoriasis
• number needed to treat
• psoriasis

Declaration of interest

P Lasalvia and Y Gil-Rojas were employees of NeuroEconomix. E Papadimitropoulos and R Burge were employees of Eli Lilly and Company when this research was conducted. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

P Lasalvia and Y Gil-Rojas contributed to the conception of study cost estimation, data analysis, and drafting of the manuscript and final manuscript review. E Papadimitropoulos, R Burge and D Rosselli contributed to the conception of the study and final revision of the manuscript. All authors read and approved the final version of the manuscript to be published.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737167.2023.2190514

Additional information

Funding

NeuroEconomix received funding from Eli Lilly and Cmopany for this study.